Australia markets closed

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
21.16+0.92 (+4.55%)
At close: 04:00PM EDT
21.25 +0.09 (+0.43%)
After hours: 05:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.24
Open20.23
Bid21.01 x 100
Ask21.32 x 100
Day's range20.20 - 21.29
52-week range4.00 - 31.01
Volume329,131
Avg. volume140,898
Market cap319.211M
Beta (5Y monthly)2.22
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

    REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper’s Board of Directors (the Board), effective as of June 18, 2024. Sep

  • GlobeNewswire

    Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

    REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24,

  • GlobeNewswire

    Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

    REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematolo